Pasithea Therapeutics (KTTA) Long-Term Deferred Tax (2021 - 2022)
Pasithea Therapeutics recorded quarterly Long-Term Deferred Tax of $931000.0 in Q4 2022, little changed quarter-over-quarter from $931000.0 in Q4 2021, and little changed year-over-year from $931000.0 in Q4 2021.
Pasithea Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $931000.0 for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax changed 0.0% year-over-year to $931000.0; the TTM figure through Dec 2022 stood at $931000.0 (changed 0.0% YoY), while the FY2022 annual figure was $931000.0, changed 0.0% from the prior year.
- Long-Term Deferred Tax came in at $931000.0 for Q4 2022 at Pasithea Therapeutics, roughly flat from $931000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $931000.0 in Q4 2021 to a low of $931000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 931,000.00 |